Altrova Health Announces Closing of Financing

(CSE: ROVA) (OTCQB: ATVHF) (FSE: WF8) Altrova Health Inc. has closed its non-brokered private placement (the "Offering") for total gross proceeds of C$669,840. The Offering was completed through the issuance of 13,396,800 units at a price of $0.05 per unit. Each unit consists of one common share and one warrant. Each whole warrant entitles the holder to purchase one additional common share at an exercise price of $0.06 per share for a period of 36 months from the date of issuance. In connection with the Offering, the company paid cash commissions of C$21,958.30 to certain eligible finders and issued 439,166 Finder's warrants. Each Finder's warrant entitles the holder to acquire one additional unit at an exercise price of $0.05 per unit for a period of 36 months from the closing date of the Offering. PowerOne Capital Markets Limited acted as finder in connection with a portion of the Offering. The net proceeds of the Offering are expected to be used to implement and commercialize the company's exclusive U.S. distribution agreement with Reliability Funding LLC, including product procurement and initial inventory, customer onboarding, training, marketing and sales activities, and for general corporate and working capital purposes. Geoff Benic, Chief Executive Officer of Altrova Health, stated that with the financing closed, the company can move on executing its exclusive U.S. distribution agreement with Reliability, and that the proceeds will support inventory, onboarding, and sales support to work toward commercial traction in the U.S. market. The company thanked its shareholders and investors for their support.

Altrova Health Reports Third Quarter Fiscal 2026 Financial Results

(CSE: ROVA) (OTCQB: ATVHF) Altrova Health Inc. reported nine-month revenue of $112,000 for the period ended June 30, 2026, up from $15,551 in the prior comparative period, marking its first commercial revenue. Gross profit for the nine-month period was $62,488, compared to $9,702 in the prior period. Gross margin was 55.8%, down from 62.4% in the prior period. Net loss and comprehensive loss for the nine months ended June 30, 2026 was $2,351,996, compared to $1,098,177 for the nine months ended June 30, 2025. The increase in net loss included a $330,640 one-time charge recognized upon the mutual termination of an exclusive license agreement in May 2026 and a $463,785 increase in non-cash share-based compensation tied to stock option vesting. General and administrative, investor relations and professional fees each declined year-over-year. The company completed a rebrand and cross-border uplisting, with shares now trading as Altrova Health Inc. on the CSE (ROVA) and OTCQB (ATVHF). The company continued NIRLAB SA device sales, expanded partnerships with Indigenous and First Nations communities, and planned a relaunch of the Drug Lab 118 Ltd. rapid detection strip portfolio.

Altrova Health Announces Launch of O-Spray Product Line and Provides Corporate Update

Altrova Health Inc. (CSE: ROVA) (OTCQB: SSPLF) announced the introduction of O-Spray™, a needle-free sublingual oral spray dosage format designed as an alternative to self-injection, pill, and syringe-based administration. The company highlighted the significant growth of the global GLP-1 receptor agonist market, valued at approximately USD 53.5 billion in 2024 and projected to reach approximately USD 315 billion by 2035. Altrova Health also reported the mutual termination of its Exclusive Territory License and Commercial Agreement with Healthy Sprays LLC, with no further commercial obligations or additional payments between the parties. The O-Spray product is positioned for use in weight management, erectile dysfunction, menopause-related care, and other indications.

Safe Supply Streaming Co Ltd. Completes Rebranding to Altrova Health Inc., with Common Shares Now Trading Under New Ticker Symbol ROVA on the CSE

Altrova Health Inc. (CSE: ROVA) (OTCQB: SSPLF) announced the completion of its corporate rebranding from Safe Supply Streaming Co Ltd. to Altrova Health Inc., with its common shares now trading under the new name and ticker symbol 'ROVA' on the Canadian Securities Exchange, effective today. The change follows shareholder approval at the Annual General Meeting held on April 8, 2026. The rebranding reflects the company's expanded focus on public health technology and detection solutions, including exclusive Canadian distribution rights for the NIRLAB SA NIRLIGHT drug analysis device and the ToxiShield fentanyl and drink-spiking detection product line. No action is required by existing shareholders regarding the name or ticker change, and previously issued share certificates remain valid. The company continues to evaluate opportunities to expand its product offerings across the public health and safety sector.